A phase 3 trial shows that the oral drug enlicitide reduces LDL cholesterol by 60% compared to placebo, according to results published in the New England Journal of Medicine. Sponsored by Merck & Co., the trial involved 2,909 participants with atherosclerosis or at risk. If approved, enlicitide could help lower heart attack and stroke risk.
New research reveals that different KRAS mutation types create distinct tumor ecosystems with varying immune responses, potentially enabling personalized treatment strategies combining mutation-specific inhibitors with immunotherapy.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07225933 |
A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal Evacuation (SURE) Procedure With the CVAC® System |
ACTIVE_NOT_RECRUITING | |
| NCT06517628 |
The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study |
RECRUITING | |
| NCT03382158 |
International PPB/DICER1 Registry |
RECRUITING |
